Latest News

Cure SMA Shares Updates on the Phase 10 SMA Industry Collaboration 

December 3, 2025
Posted in , ,

Earlier this year, Cure SMA launched an expanded Phase 10 of the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, SMA Europe, Cure […]

Read More ›

Protected: Together, We’re Changing the Story of SMA

December 3, 2025
Posted in

There is no excerpt because this is a protected post.

Read More ›

Double Your Impact this Giving Tuesday!

December 2, 2025
Posted in , ,

Today is Giving Tuesday, and there’s an incredible opportunity to double your impact!   The Luke 18:1 Foundation has stepped forward with a $50,000 gift and invited our community to double the […]

Read More ›

Novartis Receives FDA Approval of Itvisma for the Treatment of SMA

November 24, 2025
Posted in , ,

Novartis today announced  that it has received approval from the U.S. Food and Drug Administration (FDA) for Itvisma (onasemnogene abeparvovec-brve) to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA).    Itvisma […]

Read More ›

Scholar Rock and Cure SMA Share Update on Apitegromab and FDA Meeting 

November 14, 2025
Posted in , , ,

Read the Scholar Rock community statement here.   Scholar Rock recently held an in-person Type A meeting with the FDA on November 12 to discuss the Biologics License Application (BLA) […]

Read More ›

Novartis Releases Fall SMA Community Update Letter

November 3, 2025
Posted in , , ,

Novartis recently released an update on their continued collaboration with the SMA community through fundraising events and community support programs, and they will continue to provide timely updates as they […]

Read More ›
Scroll to Top